106 related articles for article (PubMed ID: 38534309)
1. Melanoma: What do all the mutations mean?
Davis EJ; Johnson DB; Sosman JA; Chandra S
Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
3. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
6. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
8. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
9. Significant and Various Effects of ML329-Induced MITF Suppression in the Melanoma Cell Line.
Nishikiori N; Watanabe M; Sato T; Furuhashi M; Okura M; Hida T; Uhara H; Ohguro H
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254754
[TBL] [Abstract][Full Text] [Related]
10.
Danishevich A; Bilyalov A; Nikolaev S; Khalikov N; Isaeva D; Levina Y; Makarova M; Nemtsova M; Chernevskiy D; Sagaydak O; Baranova E; Vorontsova M; Byakhova M; Semenova A; Galkin V; Khatkov I; Gadzhieva S; Bodunova N
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137564
[TBL] [Abstract][Full Text] [Related]
11. Phosphatase and Tensin Homolog (PTEN) Expression as a Surrogate Biomarker Correlated With the Depth of Invasion in Cutaneous Malignant Melanoma.
Sun Z; Arnouk H
Cureus; 2023 Sep; 15(9):e45295. PubMed ID: 37846279
[TBL] [Abstract][Full Text] [Related]
12. TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma.
Khan SU; Ullah Z; Shaukat H; Unab S; Jannat S; Ali W; Ali A; Irfan M; Khan MF; Cervantes-Villagrana RD
Cancer Inform; 2023; 22():11769351231177267. PubMed ID: 37667731
[TBL] [Abstract][Full Text] [Related]
13. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1.
Janka EA; Ványai B; Szabó IL; Toka-Farkas T; Várvölgyi T; Kapitány A; Szegedi A; Emri G
Front Oncol; 2023; 13():1237643. PubMed ID: 37664072
[TBL] [Abstract][Full Text] [Related]
14. Metastasectomy in Stage IV Melanoma: How and When Should We Employ It?
Faries MB; Lowe M
Ann Surg Oncol; 2023 Sep; 30(9):5312-5313. PubMed ID: 37326813
[No Abstract] [Full Text] [Related]
15. Metastasectomy for metastatic melanoma in the era of effective systemic therapy.
Schwantes IR; Sutton T; Behrens S; Fowler G; Han G; Vetto JT; Han D
Am J Surg; 2024 May; 231():65-69. PubMed ID: 37308347
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
